TP53 and ovarian carcinoma: These tumours constitute only a small fraction of ovarian carcinomas (approximately 10% of the initial set) since the large majority of affected individuals bear mutations in known cancer genes, in particular in TP53. Although cancer is usually the outcome of the alteration of several genes and multiple drivers are required for cancer progression [73], we reasoned that focusing on tumours with no mutation in known cancer genes could increase the chances to find novel drivers.